The opioid systems play an important role in mediating both physical pain and negative affects (eg 
Cognitive-Affective Neuroscience Neuroanatomy/Neurochemistry
The opioid systems comprise a number of G-protein receptor subtypes, including μ for morphine, κ for ketocyclazocine, δ for vas deferens, and ORL-1 for opioid receptor-like. 1, 2 The endogenous neuropeptide ligands for these receptors include the endorphins (eg, endomorphin), the enkephalins, the dynorphins, and the orphanin FQ or nociceptin (N/OFQ) family. These endogenous neuropeptides are, in turn, derived, respectively, from the precursors prepropiomelanocortin, preproenkephalin, preprodynorphin, and proorphanin.
μ-opioid receptors are found in particularly high densities in cingulate cortex, thalamus, periaqueductal gray, and caudate nucleus in auto-radiography and positron emission tomography studies. [3] [4] [5] Activation of μ-opioid receptors leads to altered activity in neurons in lateral amygdala, periaqueductal gray, and ventral pallidum 6, 7 by direct and indirect mechanisms. In limbic regions, increased μ-opioid receptor binding is associated with decreased perfusion, consistent with an inhibitory role. 8 Other opioid receptor subtypes have somewhat different anatomical distributions and functional networks. Opioid receptor density is also influenced by gender and age. 9 The opioid systems play a key role in mediating both analgesia and social attachment. 10, 11 Similarly, in keeping with its role as an alarm/conflict monitor, 12 activation of cingulate is associated with the affective distress of both physical pain 13, 14 and social isolation ( Figure 1 ). 15 In general, opioid systems function to signal reward, with release of endogenous opioids during the consummatory phase of motivated behavior. Exogenous opioids are analgesics and weaken the response to social separation. 16 Administration of μ-opioid agonists is associated with activation of areas that are rich in these receptors, and of reward circuitry (Figures 2 and 3 ). 17-22 23 and a similar phenomenon occurs during induced sadness in some cases of depression. 24 Indeed, opioid systems may be disrupted in a range of disorders, including depression, anxiety, autism, and self-injurious conditions. 25 In depression, an increase in μ-opioid receptor neurotransmission in anterior cingulate during induced sadness was associated with non-response to antidepressants. 24 Compared to controls with and without trauma exposure, patients with posttraumatic stress disorder (PTSD) had increased μ-opioid receptor-mediated neurotransmission in anterior cingulate, but also appeared unable to activate adequately μ-opioid receptors in amygdala and thalamus. 26 
Gene/Environment
Reduced levels of endogenous opioids may result from social isolation. 11 Opioid system function is also influenced by a number of functional polymorphisms in opioid receptor genes. 27, 28 Such environmental and genetic factors may in turn mediate vulnerability to pain symptoms, substance use disorders, 29, 30 and other psychopathology. 31 In addition, gene variants in a range of other systems may impact on opioid function. For example, worrier individuals 32 homozygous for the met158 allele of the catechol-O-methyltransferase polymorphism have diminished regional μ-opioid system responses to pain and increased pain and distress ratings compared with heterozygotes.
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Evolutionary Approaches
From an evolutionary perspective, it would not be surprising if psychobiological research demonstrated that mechanisms involved in thermoregulation and energy balance later contributed to the monitoring of social presence, and if mechanisms involved in (especially visceral) pain later contributed to emotional distress during social separation. 11, 16, 34 Conversely, evolution psychology is considerably weakened when it excludes neurobiology. 35 Indeed, opioid research highlights a close relationship between physical pain and emotions involved in social exclusion/rejection. 16 A range of other data strengthen the idea that physical and social pain operate via common proximal (psychobiological) and distal (evolutionary) mechanisms. 36 Concepts of social exclusion/rejection may be found in all times and places, and metaphors of "social pain" are present in many languages. Such ideas underpin evolutionary approaches to substance use disorders.
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Clinical Implications
DSM-IV-TR Diagnosis
The DSM-IV-TR provides diagnostic criteria for a range of opioid use disorders, including opioid abuse, dependence, intoxication, and withdrawal and opioid-induced psychotic and mood disorder. It has been suggested that the neurocircuitry underlying mother-infant attachment, in which the opioid system plays a central role, is important in mediating a range of psychopathology, 11 evident in current psychiatric nosology.
Assessment/Evaluation
Current psychiatric measures focus on symptoms characteristic of particular disorders. Rejection sensitivity has been described as a symptom of atypical depression, is increasingly being explored, 40 and a Rejection Sensitivity Questionnaire has been developed. 41 Panksepp 42 has further emphasized the importance of assessing core emotional feelings that are mediated by brainstem and limbic neural systems common to humans and lower animals. In patients with PTSD, it is important to assess opioid use. 43 
Pharmacotherapy/Psychotherapy
Morphine (named after Morpheus, the Greek god of dreams) was synthesized around 200 years ago. A range of opioids have been developed since and are used illicitly or as therapeutic agents. Higher concentrations of μ-opioid receptors in women may explain their higher sensitivity to μ-opioid agonists. 44 Opioids play a particularly important role in the management of opioid detoxification and maintenance treatment 45, 46 Buprenorphine, for example, binds with high affinity to both the μ-opioid receptor (as a partial agonist) and the κ-receptor (as an antagonist); it is able to displace heroin and other opioids that bind the μ-receptor, but has dose-limited agonist effects, and therefore, lower potential for abuse. 47 Systematic reviews of psychotherapy support its use in the integrated management of opioid use disorders. 48, 49 Opioid antagonists have proven effective for a number of substance use and impulse-control disorders, including alcohol dependence and pathological gambling. 50, 51 They have also been used in autistic disorder and self-injurious behavior. 42, 52, 53 Buprenorphine seems to exert an antidepressant effect when used for the treatment of opioid abuse. 54, 55 Furthermore, there is also preliminary evidence of the value of opioid agents in major depression, 56, 57 PTSD, [58] [59] [60] [61] and obsessive-compulsive disorder.
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Conclusion
Animal and human experiences of physical pain are embodied in a neural circuitry in which the opioid system plays a key role. In addition, more abstract cognitive-affective experiences, such as those cued by social isolation, seem to be mediated by similar circuitry. Therefore, it is perhaps not unexpected that in patients with disrupted social attachments, there are comorbid symptoms of depression and of pain, and abnormalities of the opioid system. These possibilities were anticipated by the first animal experiments in modern social neuroscience. 63, 64 Further work is needed to delineate fully the role of the opioid system in various psychopathologies, and to determine whether opioid interventions can contribute to their treatment.
